옵션 체인은 다양한 행사가격과 만기일에 대한 Gevo의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Gevo에 대한 시장 심리를 평가합니다..

Gevo (NASDAQ:GEVO) 주식, 옵션 체인

GEVO INC

Gevo

Gevo Inc is a renewable chemicals and biofuels company engaged in the development and commercialization of alternatives to petroleum-based products based on isobutanol produced from renewable feedstocks. The operating segments are the Gevo segment, GevoFuels segment, and the GevoRNG segment. By its segments, it is involved in research and development activities related to the future production of SAF, commercial opportunities for other renewable hydrocarbon products and isobutanol, including the development of its biocatalysts, and the produces-pipeline quality methane gas captured from dairy cow manure. The company derives maximum revenue from the GevoRNG segment.

Rising,Arrow,Theme,With,Abstract,High,Speed,Technology,Pov,Motion

Government

News

Financing

Contracts

After-Hours Center

Movers

CLMT

GEVO

캘러멧(NASDAQ:CLMT)와 게보(NASDAQ:GEVO)의 주식은 회사가 미국 에너지부(DOE)로부터 조건부 약정을 받은 후 수요일 시간외 거래에서 급등했다.

캘러멧과 게보의 주식이 수요일 애프터 마켓에서 급등: 무슨 일이?

Gevo Inc

Gevo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>) reported quarterly losses of $(0.09) per share which met the analyst consensus estimate. This is a 12.5 percent decrease over losses of $(0.08) per share from the same period last year. The company reported quarterly sales of $29.11 million which beat the analyst consensus estimate of $19.49 million by 49.35 percent. This is a 629.55 percent increase over sales of $3.99 million the same period last year.

Earnings

Earnings Beats

Gevo Q1 EPS $(0.09), Inline, Sales $29.11M Beat $19.49M Estimate

ABOS

ABSI

ACCS

ACHV

ACXP

ADAP

ALCO

ALLO

ASNS

AUID

AVXL

BDSX

BEAT

BKTI

BWAY

BWEN

CAMT

CAPR

CINT

CLPT

CLRB

CNCK

CYBR

DARE

DLPN

DMAC

ELMD

ETON

EXEL

FENC

FLOC

FTHM

GAIN

GAUZ

GENK

GNSS

GOCO

GRAL

GUTS

HSON

HUMA

HUYA

HYFM

HYLN

HYPR

ICMB

IMOS

INLX

IRIX

ITRM

IZEA

KOPN

KRMN

LCTX

LEGN

LOAR

LSTR

LUNR

LXRX

MASS

MBRX

MCHX

MDAI

MGNX

MPTI

NMTC

NPCE

NUTX

NUWE

NXGL

NYAX

OKLO

ONON

OPXS

PERI

PRTS

PSFE

PXLW

Earnings Scheduled For May 13, 2025

Gevo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>) will release its quarterly earnings report on Tuesday, 2025-05-13. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Gevo to report an earnings per share (EPS) of $-0.08.
Investors in Gevo are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Historical Earnings Performance</h3>
In the previous earnings release, the company beat EPS by $0.01, leading to a 9.92% drop in the share price the following trading session.

<img src="https://www.benzinga.com/files/images/story/2025/1747076657_0.png" alt="eps graph" />
<h3>Performance of Gevo Shares</h3>
Shares of Gevo were trading at $1.16 as of May 09. Over the last 52-week period, shares are up 61.2%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Insights Shared by Analysts on Gevo</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Gevo.
A total of 3 analyst ratings have been received for Gevo, with the consensus rating being Buy. The average one-year price target stands at $9.72, suggesting a potential 737.93% upside.
<h3>Comparing Ratings with Competitors</h3>
In this analysis, we delve into the analyst ratings and average 1-year price targets of Green Plains, Clean Energy Fuels and REX American Resources, three key industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for Green Plains, with an average 1-year price target of $7.3, suggesting a potential 529.31% upside.</li>
<li>Analysts currently favor an Buy trajectory for Clean Energy Fuels, with an average 1-year price target of $4.33, suggesting a potential 273.28% upside.</li>
<li>Analysts currently favor an Buy trajectory for REX American Resources, with an average 1-year price target of $50.0, suggesting a potential 4210.34% upside.</li>
</ul>
<h3>Peers Comparative Analysis Summary</h3>
The peer analysis summary provides a snapshot of key metrics for Green Plains, Clean Energy Fuels and REX American Resources, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gevo</td>
<td>Buy</td>
<td>30.32%</td>
<td>$2.25M</td>
<td>-3.54%</td>
</tr>
<tr>
<td>Green Plains</td>
<td>Neutral</td>
<td>-18.02%</td>
<td>$6.15M</td>
<td>-6.14%</td>
</tr>
<tr>
<td>Clean Energy Fuels</td>
<td>Buy</td>
<td>2.31%</td>
<td>$23.57M</td>
<td>-4.19%</td>
</tr>
<tr>
<td>REX American Resources</td>
<td>Buy</td>
<td>-15.66%</td>
<td>$17.57M</td>
<td>1.97%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Gevo is positioned at the top for Revenue Growth and Gross Profit among its peers. However, it ranks at the bottom for Return on Equity. Overall, Gevo's performance is strong in terms of revenue and profit growth, but it lags behind in generating returns for its equity holders.
<h3>Get to Know Gevo Better</h3>
Gevo Inc is a renewable chemicals and biofuels company engaged in the development and commercialization of alternatives to petroleum-based products based on isobutanol produced from renewable feedstocks. The operating segments are the Gevo segment, GevoFuels segment, and the GevoRNG segment. By its segments, it is involved in research and development activities related to the future production of SAF, commercial opportunities for other renewable hydrocarbon products and isobutanol, including the development of its biocatalysts, and the produces-pipeline quality methane gas captured from dairy cow manure. The company derives maximum revenue from the GevoRNG segment.
<h3>Financial Insights: Gevo</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Positive Revenue Trend: Examining Gevo's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 30.32% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Energy sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -308.89%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Gevo's ROE stands out, surpassing industry averages. With an impressive ROE of -3.54%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Gevo's ROA stands out, surpassing industry averages. With an impressive ROA of -2.96%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.14, Gevo adopts a prudent financial strategy, indicating a balanced approach to debt management.
<a href="https://www.benzinga.com/quote/GEVO/earnings">To track all earnings releases for Gevo visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insights Ahead: Gevo's Quarterly Earnings

Gevo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>) announced Wednesday that it has <a href="https://www.benzinga.com/pressreleases/25/04/g44710157/gevo-and-future-energy-global-sign-saf-scope-1-and-scope-3-voluntary-carbon-credit-offtake-agreeme" target="_blank" rel="noreferrer noopener">entered a multi-year offtake agreement</a> with Future Energy Global (FEG) to supply carbon abatement credits tied to 10 million gallons per year of sustainable aviation fuel (SAF).
The agreement enables airlines and corporations to reduce their Scope 1 and Scope 3 emissions. The deal includes an option for FEG to increase the offtake volume in the future.
The deal is expected to support Gevo's financing of its ATJ-60 production facility in Lake Preston, South Dakota. Backed by a $1.63 billion conditional loan guarantee from the U.S. Department of Energy and equity from project-level investors, the plant is designed to produce 60 million gallons of low-emission SAF annually at a cost comparable to conventional jet fuel.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/guidance/25/02/43442930/gevo-buys-ethanol-ccs-assets-secures-additional-100-million-potential-funding-for-net-zero-north-expansion" rel="noreferrer noopener">Gevo Buys Ethanol &amp; CCS Assets, Secures Additional $100 Million Potential Funding For Net-Zero North Expansion</a>
With global aviation targeting net-zero emissions by 2050—and SAF projected to deliver two-thirds of the required reductions—production must scale over 400-fold. FEG addresses this challenge by offering SAF-derived Scope 1 and Scope 3 credits to buyers who can't access physical fuel, using a "Book and Claim" model that separates environmental attributes from fuel logistics to reduce costs and emissions.
Gevo CEO Dr. Patrick Gruber emphasized that a functional Book and Claim market can help unlock faster SAF adoption, including for aircraft lessors who own nearly half the global commercial fleet.
By commercializing SAF-related carbon credits and offering predictable pricing, FEG's business model helps bridge financing gaps, enabling suppliers like Gevo to expand more rapidly. While its initial focus is aviation, FEG's credit solutions extend to the marine and land transport sectors.
Price Action: GEVO shares are trading lower by 0.98% at $1.01 at the last check Wednesday.
Photo: Shutterstock

Gevo Seals SAF Offtake With FEG, Backed By DOE Loan And Net-Zero Industry Momentum

Gevo Signs SAF Scope 1 And Scope 3 Voluntary Carbon Credit Offtake Agreement With Future Energy Global

Gevo's Verity Partners With Minnesota Soybean Processors To Track And Verify Sustainable Agriculture Attributes

Throughout the last three months, 4 analysts have evaluated Gevo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>), offering a diverse set of opinions from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $10.79, a high estimate of $14.00, and a low estimate of $1.15. A decline of 4.6% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1743631272_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Gevo. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manav Gupta</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$1.15</td>
<td>$3.25</td>
</tr>
<tr>
<td>Amit Dayal</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Amit Dayal</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Amit Dayal</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Gevo. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Gevo compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Gevo's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Gevo's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/GEVO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Gevo analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Get to Know Gevo Better</h2>
Gevo Inc is a renewable chemicals and biofuels company engaged in the development and commercialization of alternatives to petroleum-based products based on isobutanol produced from renewable feedstocks. Its operating segments are the Gevo segment, Renewable Natural Gas Segment, and the Agri-Energy segment. By its segments, it is involved in research and development activities related to the future production of SAF, commercial opportunities for other renewable hydrocarbon products and isobutanol, including the development of its biocatalysts, and the produces-pipeline quality methane gas captured from dairy cow manure.
<h3>Key Indicators: Gevo's Financial Health</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Gevo displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 30.32%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Energy sector.
Net Margin: Gevo's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -308.89%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -3.54%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Gevo's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -2.96%, the company showcases efficient use of assets and strong financial health.
Debt Management: Gevo's debt-to-equity ratio is below the industry average. With a ratio of 0.14, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Significance of Analyst Ratings Explained</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Expert Outlook: Gevo Through The Eyes Of 4 Analysts

UBS analyst Manav Gupta maintains Gevo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>) with a Neutral and lowers the price target from $3.25 to $1.15.

Price Target

UBS Maintains Neutral on Gevo, Lowers Price Target to $1.15

WIIM

Gevo shares are trading lower after the company reported a Q4 EPS miss.

HC Wainwright &amp; Co. analyst Amit Dayal reiterates Gevo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>) with a Buy and maintains $14 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Gevo, Maintains $14 Price Target

Gevo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $(0.07) by 14.29 percent. This is unchanged from the same period last year.

Earnings Misses

Gevo Q4 2024 GAAP EPS $(0.08) Misses $(0.07) Estimate

<h3>Companies Reporting Before The Bell</h3>
• Tsakos Energy Navigation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEN#NYSE">TEN</a>) is projected to report quarterly earnings at $0.40 per share on revenue of $154.43 million. 
• Worksport (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKSP#NASDAQ">WKSP</a>) is projected to report quarterly loss at $1.40 per share on revenue of $2.90 million. 
• PDS Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDSB#NASDAQ">PDSB</a>) is projected to report earnings for its fourth quarter. 
• FitLife Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTLF#NASDAQ">FTLF</a>) is estimated to report quarterly earnings at $0.20 per share on revenue of $14.95 million. 
• ADC Therapeutics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADCT#NYSE">ADCT</a>) is expected to report quarterly loss at $0.35 per share on revenue of $19.67 million. 
• Telesat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSAT#NASDAQ">TSAT</a>) is expected to report earnings for its fourth quarter. 
• Acumen Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABOS#NASDAQ">ABOS</a>) is expected to report earnings for its fourth quarter. 
• Bitfarms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BITF#NASDAQ">BITF</a>) is estimated to report quarterly loss at $0.04 per share on revenue of $53.82 million. 
• Winnebago Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WGO#NYSE">WGO</a>) is expected to report quarterly earnings at $0.19 per share on revenue of $608.95 million. 
• BK Technologies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BKTI#AMEX">BKTI</a>) is estimated to report quarterly earnings at $0.35 per share on revenue of $16.80 million. 
• Edap TMS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDAP#NASDAQ">EDAP</a>) is estimated to report quarterly loss at $0.11 per share on revenue of $20.83 million. 
• TriSalus Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLSI#NASDAQ">TLSI</a>) is likely to report quarterly loss at $0.35 per share on revenue of $8.24 million. 
• BIO-key Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKYI#NASDAQ">BKYI</a>) is likely to report quarterly loss at $0.35 per share on revenue of $2.29 million. 
• Icecure Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICCM#NASDAQ">ICCM</a>) is expected to report quarterly loss at $0.07 per share on revenue of $1.07 million. 
• Jiayin Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFIN#NASDAQ">JFIN</a>) is likely to report earnings for its fourth quarter. 
• Ascentage Pharma Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPG#NASDAQ">AAPG</a>) is projected to report earnings for its fourth quarter. 
• Urban One (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UONEK#NASDAQ">UONEK</a>) is estimated to report earnings for its fourth quarter. 
• Urban One (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UONE#NASDAQ">UONE</a>) is projected to report earnings for its fourth quarter. 
• TD Synnex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNX#NYSE">SNX</a>) is likely to report quarterly earnings at $2.91 per share on revenue of $14.79 billion. 
• Sachem Cap (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SACH#AMEX">SACH</a>) is projected to report quarterly loss at $0.46 per share on revenue of $14.49 million. 
• Ermenegildo Zegna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZGN#NYSE">ZGN</a>) is likely to report earnings for its Fiscal Year 2024. 
• Innate Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPHA#NASDAQ">IPHA</a>) is projected to report earnings for its Fiscal Year 2024. 
<h3>Companies Reporting After The Bell</h3>
• Dolphin Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLPN#NASDAQ">DLPN</a>) is likely to report quarterly earnings at $0.04 per share on revenue of $13.52 million. 
• Relmada Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLMD#NASDAQ">RLMD</a>) is projected to report earnings for its fourth quarter. 
• Draganfly (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPRO#NASDAQ">DPRO</a>) is projected to report quarterly loss at $0.66 per share on revenue of $1.45 million. 
• Gevo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>) is projected to report quarterly loss at $0.09 per share on revenue of $3.85 million. 
• SeaStar Medical Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICU#NASDAQ">ICU</a>) is likely to report earnings for its fourth quarter. 
• INmune Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) is projected to report earnings for its fourth quarter. 
• TMC Metals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMC#NASDAQ">TMC</a>) is estimated to report earnings for its fourth quarter. 
• Strata Skin Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSKN#NASDAQ">SSKN</a>) is expected to report quarterly loss at $0.40 per share on revenue of $9.03 million. 
• IZEA Worldwide (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IZEA#NASDAQ">IZEA</a>) is expected to report quarterly loss at $0.08 per share on revenue of $13.00 million. 
• Yxt.Com Group Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YXT#NASDAQ">YXT</a>) is expected to report earnings for its fourth quarter. 
• TSS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSSI#NASDAQ">TSSI</a>) is expected to report earnings for its fourth quarter. 
• BioRestorative Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRTX#NASDAQ">BRTX</a>) is likely to report quarterly loss at $0.27 per share on revenue of $475 thousand. 
• Direct Digital Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRCT#NASDAQ">DRCT</a>) is likely to report quarterly loss at $0.67 per share on revenue of $12.31 million. 
• Faraday Future (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFAI#NASDAQ">FFAI</a>) is expected to report earnings for its fourth quarter. 
• 374Water (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCWO#NASDAQ">SCWO</a>) is likely to report quarterly loss at $0.02 per share on revenue of $100 thousand. 
• Lantern Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRN#NASDAQ">LTRN</a>) is estimated to report earnings for its fourth quarter. 
• Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) is projected to report quarterly loss at $0.95 per share on revenue of $920 thousand. 
• Unusual Machines (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/UMAC#AMEX">UMAC</a>) is likely to report earnings for its fourth quarter. 
• BioAtla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAB#NASDAQ">BCAB</a>) is expected to report earnings for its fourth quarter. 
• Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) is projected to report quarterly loss at $0.51 per share on revenue of $1.19 million. 
• VirTra (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTSI#NASDAQ">VTSI</a>) is projected to report quarterly earnings at $0.07 per share on revenue of $8.09 million. 
• Forian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORA#NASDAQ">FORA</a>) is estimated to report quarterly earnings at $0.02 per share on revenue of $5.37 million. 
• Spero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRO#NASDAQ">SPRO</a>) is likely to report quarterly loss at $0.31 per share on revenue of $6.20 million. 
• Beachbody Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BODI#NYSE">BODI</a>) is likely to report quarterly loss at $1.52 per share on revenue of $81.71 million. 
• Stardust Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDST#NASDAQ">SDST</a>) is expected to report earnings for its fourth quarter. 
• Valhi (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VHI#NYSE">VHI</a>) is expected to report quarterly earnings at $0.03 per share on revenue of $19.48 million. 
• Nutex Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUTX#NASDAQ">NUTX</a>) is projected to report quarterly earnings at $0.00 per share on revenue of $81.13 million. 
• Iridex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRIX#NASDAQ">IRIX</a>) is projected to report quarterly loss at $0.05 per share on revenue of $12.80 million. 
• AAR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIR#NYSE">AIR</a>) is projected to report quarterly earnings at $0.96 per share on revenue of $679.95 million. 
• Oxford Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXM#NYSE">OXM</a>) is expected to report quarterly earnings at $1.28 per share on revenue of $383.94 million. 
• P3 Health Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIII#NASDAQ">PIII</a>) is expected to report quarterly loss at $0.17 per share on revenue of $385.80 million. 
• Co-Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CODX#NASDAQ">CODX</a>) is likely to report quarterly loss at $0.34 per share on revenue of $375 thousand. 
• Argan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGX#NYSE">AGX</a>) is estimated to report quarterly earnings at $1.11 per share on revenue of $212.05 million. 
• HireQuest (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQI#NASDAQ">HQI</a>) is likely to report quarterly earnings at $0.19 per share on revenue of $9.30 million. 
• Lululemon Athletica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) is expected to report quarterly earnings at $5.65 per share on revenue of $3.52 billion. 
• Clearside Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSD#NASDAQ">CLSD</a>) is likely to report quarterly loss at $0.11 per share on revenue of $294 thousand. 
• KULR Tech Gr (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KULR#AMEX">KULR</a>) is estimated to report quarterly loss at $0.02 per share on revenue of $2.87 million. 
• Blaize Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BZAI#NASDAQ">BZAI</a>) is expected to report earnings for its fourth quarter. 
• Sky Harbour Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKYH#NYSE">SKYH</a>) is expected to report quarterly loss at $0.06 per share on revenue of $4.15 million. 
• Better Choice Co (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BTTR#AMEX">BTTR</a>) is likely to report earnings for its fourth quarter. 
• Pulse Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLSE#NASDAQ">PLSE</a>) is likely to report earnings for its fourth quarter. 
• Braze (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRZE#NASDAQ">BRZE</a>) is expected to report quarterly earnings at $0.04 per share on revenue of $155.25 million. 
• Lulus Fashion Lounge (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVLU#NASDAQ">LVLU</a>) is likely to report quarterly loss at $0.14 per share on revenue of $68.43 million. 
• Spectral AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDAI#NASDAQ">MDAI</a>) is expected to report quarterly loss at $0.14 per share on revenue of $6.83 million. 
• Barfresh Food Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRFH#NASDAQ">BRFH</a>) is expected to report quarterly loss at $0.01 per share on revenue of $4.17 million. 
• Abacus Global Management (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABL#NASDAQ">ABL</a>) is expected to report quarterly earnings at $0.14 per share on revenue of $30.18 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AAPG

ADCT

BCAB

BITF

BKYI

The Beachbody Company, Inc. Class A Common Stock

BODI

BRFH

BRTX

BRZE

BTTR

BZAI

CLSD

CODX

DPRO

DRCT

EDAP

Faraday Future Intelligent Electric Inc. - Class A Common Stock

FFAI

FORA

FTLF

GOVX

ICCM

INMB

IPHA

JFIN

KULR

LTRN

LULU

LVLU

PDSB

PIII

PLSE

PSTV

RLMD

SACH

SCWO

SDST

SKYH

SPRO

SSKN

TLSI

TSAT

TSSI

UMAC

UONE

UONEK

VTSI

WKSP

Earnings Scheduled For March 27, 2025

Gevo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>) will release its quarterly earnings report on Thursday, 2025-03-27. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Gevo to report an earnings per share (EPS) of $-0.09.
Investors in Gevo are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Earnings Track Record</h3>
In the previous earnings release, the company missed EPS by $0.02, leading to a 16.32% drop in the share price the following trading session.
Here's a look at Gevo's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.07</td>
<td>-0.09</td>
<td>-0.07</td>
<td>-0.05</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.09</td>
<td>-0.09</td>
<td>-0.08</td>
<td>-0.08</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-16.0%</td>
<td>0.0%</td>
<td>-0.0%</td>
<td>-4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1743015787_0.png" alt="eps graph" />
<h3>Tracking Gevo's Stock Performance</h3>
Shares of Gevo were trading at $1.25 as of March 25. Over the last 52-week period, shares are up 60.66%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analysts' Take on Gevo</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Gevo.
A total of 2 analyst ratings have been received for Gevo, with the consensus rating being Buy. The average one-year price target stands at $14.0, suggesting a potential 1020.0% upside.
<h3>Analyzing Analyst Ratings Among Peers</h3>
The below comparison of the analyst ratings and average 1-year price targets of Green Plains, Clean Energy Fuels and Par Pacific Hldgs, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.
<ul>
<li>The consensus outlook from analysts is an Neutral trajectory for Green Plains, with an average 1-year price target of $8.25, indicating a potential 560.0% upside.</li>
<li>Analysts currently favor an Buy trajectory for Clean Energy Fuels, with an average 1-year price target of $4.0, suggesting a potential 220.0% upside.</li>
<li>As per analysts' assessments, Par Pacific Hldgs is favoring an Outperform trajectory, with an average 1-year price target of $22.0, suggesting a potential 1660.0% upside.</li>
</ul>
<h3>Peers Comparative Analysis Summary</h3>
The peer analysis summary offers a detailed examination of key metrics for Green Plains, Clean Energy Fuels and Par Pacific Hldgs, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gevo</td>
<td>Buy</td>
<td>-56.60%</td>
<td>$-579K</td>
<td>-4.12%</td>
</tr>
<tr>
<td>Green Plains</td>
<td>Neutral</td>
<td>-18.02%</td>
<td>$6.15M</td>
<td>-6.14%</td>
</tr>
<tr>
<td>Clean Energy Fuels</td>
<td>Buy</td>
<td>2.31%</td>
<td>$23.57M</td>
<td>-4.19%</td>
</tr>
<tr>
<td>Par Pacific Hldgs</td>
<td>Outperform</td>
<td>-16.09%</td>
<td>$119.04M</td>
<td>-4.56%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Gevo is at the bottom for Revenue Growth and Gross Profit, with negative values. It is also at the bottom for Return on Equity, with a negative percentage. Gevo's Consensus rating is 'Buy', which is in line with one other peer. Overall, Gevo ranks lower compared to its peers in terms of financial performance metrics.
<h3>Discovering Gevo: A Closer Look</h3>
Gevo Inc is a renewable chemicals and biofuels company engaged in the development and commercialization of alternatives to petroleum-based products based on isobutanol produced from renewable feedstocks. Its operating segments are the Gevo segment, Renewable Natural Gas Segment, and the Agri-Energy segment. By its segments, it is involved in research and development activities related to the future production of SAF, commercial opportunities for other renewable hydrocarbon products and isobutanol, including the development of its biocatalysts, and the produces-pipeline quality methane gas captured from dairy cow manure.
<h3>Unraveling the Financial Story of Gevo</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining Gevo's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately -56.6% in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Energy sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -1076.64%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Gevo's ROE stands out, surpassing industry averages. With an impressive ROE of -4.12%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -3.46%, the company showcases effective utilization of assets.
Debt Management: Gevo's debt-to-equity ratio is below the industry average. With a ratio of 0.14, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<a href="https://www.benzinga.com/quote/GEVO/earnings">To track all earnings releases for Gevo visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What to Expect from Gevo's Earnings

<a href="https://www.axios.com/pro/climate-deals/newsletters/2025/03/25/climate-800m-spv">https://www.axios.com/pro/climate-deals/newsletters/2025/03/25/climate-800m-spv</a>
&nbsp;
Renewable fuels producer Gevo is preparing to raise about $800 million in a special purpose vehicle to build a production plant in South Dakota. Why it matters: The company will raise the funds from infrastructure firms, strategic backers and impact investors.

'Gevo To Raise $800M In Biofuels SPV' - Axios

Gevo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>) announced today that it will host its rescheduled conference call on March 27, 2025, at 4:30 p.m. ET (2:30 p.m. MT) to report its financial results for the fourth quarter ended December 31, 2024.
To participate in the live call, please register through the following event weblink:&nbsp;&nbsp; <a href="https://www.globenewswire.com/Tracker?data=LosSaMa6P0qgzY4GHUaug-JKN0uf_N6EuIUjxlbqpUrIt7vezwevK2x6tWDk8U39Fsl3ZjNeldHpcvN6-20rp1XWyI-HEACwGddVFv5Qx7OyHv15X8EKDK8OWfmvNX-CHLg6edmFX4eW8UL3TpBGFLwtX0YqYmkqAXk4tYcwKeJ2d_GnE1upClAJQGd01Suvgj-GfmdR0i_n-YLerIadoKY0-tncdO6HDSnbiWuCZ0Q=">https://register.vevent.com/register/BIfe02700a31384d12946e60bf35964cb8</a>&nbsp;
After registering, participants will be provided with a dial-in number and pin.

Events

Gevo Reschedules Conference Call On March 27, 2025, At 4:30 p.m. ET To Report Its Financial Results For Q4

CSAN

GPRE

MPLX

NCSM

NEHC

OPAL

TRGP

Shares of oil and gas companies are trading higher amid weakness in the dollar after the US launched strikes on Houthi targets. Additionally, strong Chinese economic data could be lifting the demand outlook.

Guidance

Gevo Reiterates Potential Adj. EBITDA Growth Targets For 2025

Gevo Announces That It Will Delay The Issuance Of Its Q4 And FY24 Earnings Release And Investor Conference Call Previously Scheduled for March 6, 2025

<h3>Companies Reporting Before The Bell</h3>
• Priority Tech Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTH#NASDAQ">PRTH</a>) is expected to report quarterly earnings at $0.07 per share on revenue of $227.93 million. 
• KVH Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KVHI#NASDAQ">KVHI</a>) is projected to report quarterly loss at $0.07 per share on revenue of $28.12 million. 
• Dingdong (Cayman) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DDL#NYSE">DDL</a>) is projected to report quarterly earnings at $0.00 per share on revenue of $793.81 million. 
• Seanergy Maritime Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHIP#NASDAQ">SHIP</a>) is likely to report quarterly earnings at $0.43 per share on revenue of $40.15 million. 
• Dynagas LNG Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLNG#NYSE">DLNG</a>) is estimated to report quarterly earnings at $0.28 per share on revenue of $38.34 million. 
• ALX Oncology Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALXO#NASDAQ">ALXO</a>) is likely to report earnings for its fourth quarter. 
• Ranpak Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PACK#NYSE">PACK</a>) is expected to report quarterly loss at $0.02 per share on revenue of $100.41 million. 
• VerifyMe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRME#NASDAQ">VRME</a>) is likely to report quarterly loss at $0.04 per share on revenue of $8.21 million. 
• Xeris Biopharma Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XERS#NASDAQ">XERS</a>) is likely to report quarterly loss at $0.05 per share on revenue of $60.00 million. 
• Stevanato Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STVN#NYSE">STVN</a>) is projected to report quarterly earnings at $0.20 per share on revenue of $352.00 million. 
• Phathom Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHAT#NASDAQ">PHAT</a>) is projected to report quarterly loss at $1.07 per share on revenue of $26.04 million. 
• John Wiley &amp; Sons (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLYB#NYSE">WLYB</a>) is likely to report earnings for its third quarter. 
• John Wiley &amp; Sons (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLY#NYSE">WLY</a>) is projected to report quarterly earnings at $0.45 per share on revenue of $401.10 million. 
• Turning Point Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPB#NYSE">TPB</a>) is projected to report quarterly earnings at $0.75 per share on revenue of $102.27 million. 
• Macy's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/M#NYSE">M</a>) is estimated to report quarterly earnings at $1.91 per share on revenue of $7.84 billion. 
• Burlington Stores (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BURL#NYSE">BURL</a>) is likely to report quarterly earnings at $3.76 per share on revenue of $3.29 billion. 
• Kroger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KR#NYSE">KR</a>) is expected to report quarterly earnings at $1.09 per share on revenue of $34.87 billion. 
• Mind Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNMD#NASDAQ">MNMD</a>) is projected to report earnings for its fourth quarter. 
• JD.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) is estimated to report quarterly earnings at $0.80 per share on revenue of $45.16 billion. 
• Delcath Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>) is estimated to report quarterly loss at $0.02 per share on revenue of $12.42 million. 
• Cracker Barrel Old (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBRL#NASDAQ">CBRL</a>) is likely to report quarterly earnings at $0.41 per share on revenue of $836.96 million. 
• GMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMS#NYSE">GMS</a>) is projected to report quarterly earnings at $1.40 per share on revenue of $1.29 billion. 
• Superior Industries Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUP#NYSE">SUP</a>) is expected to report quarterly loss at $0.60 per share on revenue of $300.28 million. 
• Evogene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGN#NASDAQ">EVGN</a>) is expected to report quarterly loss at $0.73 per share on revenue of $3.62 million. 
• Marex Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRX#NASDAQ">MRX</a>) is expected to report quarterly earnings at $0.61 per share on revenue of $370.82 million. 
• ProFrac Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACDC#NASDAQ">ACDC</a>) is likely to report quarterly loss at $0.23 per share on revenue of $498.50 million. 
• Toro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TTC#NYSE">TTC</a>) is expected to report quarterly earnings at $0.63 per share on revenue of $1.01 billion. 
• Sunrise Realty Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUNS#NASDAQ">SUNS</a>) is projected to report earnings for its fourth quarter. 
• Vanguard Extended Duration Treasury ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EDV#NYSE">EDV</a>) is projected to report earnings for its fourth quarter. 
• BrightSpring Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTSG#NASDAQ">BTSG</a>) is likely to report quarterly earnings at $0.20 per share on revenue of $2.95 billion. 
• America's Car-Mart (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMT#NASDAQ">CRMT</a>) is expected to report quarterly earnings at $0.17 per share on revenue of $273.39 million. 
• BlackSky Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKSY#NYSE">BKSY</a>) is projected to report quarterly loss at $0.26 per share on revenue of $34.23 million. 
• Distribution Solns Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSGR#NASDAQ">DSGR</a>) is likely to report quarterly earnings at $0.33 per share on revenue of $463.80 million. 
• Hippo Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIPO#NYSE">HIPO</a>) is projected to report quarterly earnings at $0.07 per share on revenue of $98.75 million. 
• Polestar Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNY#NASDAQ">PSNY</a>) is expected to report quarterly loss at $0.15 per share on revenue of $634.04 million. 
• Canadian Natural Res (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNQ#NYSE">CNQ</a>) is likely to report quarterly earnings at $0.95 per share on revenue of $8.90 billion. 
• Real Brokerage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REAX#NASDAQ">REAX</a>) is likely to report quarterly loss at $0.05 per share on revenue of $282.20 million. 
• Myers Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MYE#NYSE">MYE</a>) is likely to report quarterly earnings at $0.10 per share on revenue of $203.10 million. 
• TORM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRMD#NASDAQ">TRMD</a>) is expected to report quarterly earnings at $0.74 per share on revenue of $280.86 million. 
• BJ's Wholesale Club (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BJ#NYSE">BJ</a>) is expected to report quarterly earnings at $0.86 per share on revenue of $5.30 billion. 
<h3>Companies Reporting After The Bell</h3>
• Samsara (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IOT#NYSE">IOT</a>) is expected to report quarterly earnings at $0.07 per share on revenue of $335.35 million. 
• Lexicon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) is estimated to report quarterly loss at $0.12 per share on revenue of $6.48 million. 
• DXP Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXPE#NASDAQ">DXPE</a>) is estimated to report quarterly earnings at $0.86 per share on revenue of $431.00 million. 
• Reliance Global Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RELI#NASDAQ">RELI</a>) is projected to report earnings for its fourth quarter. 
• Cherry Hill Mortgage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHMI#NYSE">CHMI</a>) is expected to report quarterly earnings at $0.19 per share on revenue of $2.37 million. 
• Research Frontiers (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REFR#NASDAQ">REFR</a>) is expected to report earnings for its fourth quarter. 
• Silvercrest Asset Mgmt Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAMG#NASDAQ">SAMG</a>) is likely to report quarterly earnings at $0.30 per share on revenue of $31.97 million. 
• Xtant Medical Hldgs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/XTNT#AMEX">XTNT</a>) is projected to report quarterly loss at $0.02 per share on revenue of $31.80 million. 
• Cango (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CANG#NYSE">CANG</a>) is likely to report earnings for its fourth quarter. 
• ModivCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MODV#NASDAQ">MODV</a>) is projected to report quarterly earnings at $0.69 per share on revenue of $717.27 million. 
• Comstock (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/LODE#AMEX">LODE</a>) is projected to report quarterly loss at $0.20 per share on revenue of $700 thousand. 
• Marchex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHX#NASDAQ">MCHX</a>) is likely to report quarterly loss at $0.02 per share on revenue of $12.01 million. 
• GEN Restaurant Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GENK#NASDAQ">GENK</a>) is likely to report quarterly loss at $0.03 per share on revenue of $49.77 million. 
• CytomX Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTMX#NASDAQ">CTMX</a>) is estimated to report quarterly loss at $0.13 per share on revenue of $13.53 million. 
• Atea Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVIR#NASDAQ">AVIR</a>) is estimated to report earnings for its fourth quarter. 
• National CineMedia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCMI#NASDAQ">NCMI</a>) is projected to report quarterly earnings at $0.31 per share on revenue of $83.72 million. 
• Fidus Investment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FDUS#NASDAQ">FDUS</a>) is estimated to report quarterly earnings at $0.52 per share on revenue of $36.66 million. 
• Molecular Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOLN#NASDAQ">MOLN</a>) is estimated to report quarterly loss at $1.61 per share on revenue of $5.00 million. 
• IDT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IDT#NYSE">IDT</a>) is expected to report earnings for its second quarter. 
• Smith &amp; Wesson Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWBI#NASDAQ">SWBI</a>) is likely to report quarterly earnings at $0.02 per share on revenue of $119.46 million. 
• Arcturus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>) is estimated to report quarterly loss at $0.51 per share on revenue of $45.92 million. 
• Serve Robotics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERV#NASDAQ">SERV</a>) is expected to report quarterly loss at $0.13 per share on revenue of $254 thousand. 
• Clarus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLAR#NASDAQ">CLAR</a>) is expected to report quarterly earnings at $0.09 per share on revenue of $69.03 million. 
• Guidewire Software (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWRE#NYSE">GWRE</a>) is expected to report quarterly earnings at $0.52 per share on revenue of $285.83 million. 
• Elutia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELUT#NASDAQ">ELUT</a>) is likely to report quarterly loss at $0.25 per share on revenue of $6.40 million. 
• MeridianLink (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLNK#NYSE">MLNK</a>) is projected to report quarterly earnings at $0.08 per share on revenue of $78.53 million. 
• Asure Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASUR#NASDAQ">ASUR</a>) is estimated to report quarterly earnings at $0.17 per share on revenue of $30.82 million. 
• BigBear.ai Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBAI#NYSE">BBAI</a>) is projected to report quarterly loss at $0.05 per share on revenue of $54.17 million. 
• Traeger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COOK#NYSE">COOK</a>) is projected to report quarterly earnings at $0.01 per share on revenue of $164.62 million. 
• Domo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOMO#NASDAQ">DOMO</a>) is projected to report quarterly loss at $0.16 per share on revenue of $78.00 million. 
• AerSale (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASLE#NASDAQ">ASLE</a>) is estimated to report quarterly earnings at $0.08 per share on revenue of $91.78 million. 
• Guild Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GHLD#NYSE">GHLD</a>) is projected to report quarterly earnings at $0.37 per share on revenue of $272.74 million. 
• Hudson Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HDSN#NASDAQ">HDSN</a>) is expected to report quarterly loss at $0.02 per share on revenue of $37.96 million. 
• a.k.a. Brands Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AKA#NYSE">AKA</a>) is projected to report quarterly loss at $0.23 per share on revenue of $154.49 million. 
• American Outdoor Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AOUT#NASDAQ">AOUT</a>) is likely to report quarterly earnings at $0.10 per share on revenue of $56.78 million. 
• Funko (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FNKO#NASDAQ">FNKO</a>) is likely to report quarterly earnings at $0.00 per share on revenue of $285.79 million. 
• Gevo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>) is likely to report quarterly loss at $0.07 per share on revenue of $3.95 million. 
• American Public Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APEI#NASDAQ">APEI</a>) is estimated to report quarterly earnings at $0.62 per share on revenue of $161.78 million. 
• El Pollo Loco Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOCO#NASDAQ">LOCO</a>) is projected to report quarterly earnings at $0.14 per share on revenue of $115.83 million. 
• Noodles (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDLS#NASDAQ">NDLS</a>) is likely to report quarterly loss at $0.14 per share on revenue of $121.36 million. 
• Potbelly (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBPB#NASDAQ">PBPB</a>) is projected to report quarterly earnings at $0.05 per share on revenue of $115.23 million. 
• Loma Negra Cia Industria (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOMA#NYSE">LOMA</a>) is estimated to report quarterly loss at $0.10 per share on revenue of $221.13 million. 
• Granite Ridge Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRNT#NYSE">GRNT</a>) is expected to report quarterly earnings at $0.13 per share on revenue of $104.93 million. 
• Invesco Dorsey Wright Industrials Momentum ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRN#NASDAQ">PRN</a>) is likely to report quarterly loss at $0.47 per share on revenue of $5.92 million. 
• Profound Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROF#NASDAQ">PROF</a>) is expected to report quarterly loss at $0.34 per share on revenue of $5.92 million. 
• Gap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>) is projected to report quarterly earnings at $0.38 per share on revenue of $4.07 billion. 
• Hewlett Packard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>) is projected to report quarterly earnings at $0.50 per share on revenue of $7.82 billion. 
• HASHICORP INC CL A (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCP#NASDAQ">HCP</a>) is projected to report quarterly earnings at $0.08 per share on revenue of $175.71 million. 
• ACCESS Newswire (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ACCS#AMEX">ACCS</a>) is likely to report quarterly earnings at $0.23 per share on revenue of $7.38 million. 
• Information Servs Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/III#NASDAQ">III</a>) is expected to report quarterly earnings at $0.05 per share on revenue of $57.62 million. 
• Full House Resorts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLL#NASDAQ">FLL</a>) is likely to report quarterly loss at $0.19 per share on revenue of $75.78 million. 
• Willdan Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLDN#NASDAQ">WLDN</a>) is expected to report quarterly earnings at $0.57 per share on revenue of $145.00 million. 
• Broadcom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) is expected to report quarterly earnings at $1.47 per share on revenue of $14.62 billion. 
• Ero Copper (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ERO#NYSE">ERO</a>) is estimated to report earnings for its fourth quarter. 
• Velocity Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEL#NYSE">VEL</a>) is estimated to report quarterly earnings at $0.48 per share on revenue of $42.70 million. 
• Cooper Companies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COO#NASDAQ">COO</a>) is expected to report quarterly earnings at $0.92 per share on revenue of $980.87 million. 
• Costco Wholesale (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) is expected to report quarterly earnings at $4.01 per share on revenue of $62.61 billion. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

Gevo

Gevo (GEVO) 옵션

Gevo (NASDAQ:GEVO) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌